Pharma Companies Urge US and EU to Exempt Medical Goods from Tariff Wars

Major drugmakers are pressing the Trump administration and European Union officials to exclude medical goods from the escalating tariff wars. The industry fears that tariffs could lead to price hikes on top-selling medicines, including Novo Nordisk’s weight-loss drug Wegovy and Merck’s cancer immunotherapy Keytruda.

Pharmaceutical firms argue that imposing tariffs on essential medicines could increase healthcare costs and limit patient access to critical treatments. Negotiations continue as stakeholders seek to protect the global medical supply chain